№97. Main events in oncology in 2023

Advances in fundamental and translational oncology: the year 2023 update

DOI 10.31917/2501001

E.N. Imyanitov
Optimal dosage and duration of treatment for patients with malignant tumors. are approved guidelines always correct?

DOI 10.31917/2501008

M.A. Krasavina, V.M. Moiseenko
Is it possible to get survival benefit in advanced malignant tumors? (datA from trials, critical aspects)

DOI 10.31917/2501017

A.I. Semenova
Application of biomedical cell products based on natural killer cells and cytokine-induced killer cells for the treatment of oncological diseases

DOI 10.31917/2501025

A.O. Malasheuskaya, N.G. Antonevich, A.Y. Hancharou
MSI-H cancer – what has happened in the last year?

DOI 10.31917/2501034

V.A. Chubenko
Long-term outcomes of neoadjuvant endocrine therapy versus chemotherapy in luminal HER2-breast cancer

DOI 10.31917/2501041

N.K. Abduloeva, V.M. Moiseenko, F.V. Moiseenko. O.A. Skripko, M.V. Scriabin, R.A. Ryanjina
Comparative evaluation of robot-assisted, laparoscopic and open surgical interventions in the combined treatment of stomach cance

DOI 10.31917/2501049

S.A. Kovalenko., I.I. Dzidzava, D.V. Gladyshev, V.Yu. Svitich, M.E. Moiseev, V.A. Vetoshkin, S.S. Gnedash, G.B. Pavlinov, A.S. Skobaro
Modern approa hes to the treatment of primary multiple unilateral synchronous lung tumors (literature review)

DOI 10.31917/2501063

I.V. Mosin, S.M. Nuraliev, A.G. Pavlov, V.M. Moiseenko
The role of pirnas in oncogenesis: a review of associations

DOI 10.31917/2501074

S.M. Shlyapnikov, A.A. Agumava, A.V. Panchenko, S.V. Orlov